Breast Cancer Archives

Oncotarget News

Why Some Breast Cancer Treatments Stop Working

March 25, 2025

Innovations in therapeutic strategies, coupled with a deeper understanding of breast cancer biology, will be essential for advancing personalized medicine and improving clinical outcomes.”BUFFALO, NY - March 25, 2025 – A... read more

Oncotarget

Rethinking Breast Cancer Screening: New Insights on Overdiagnosis

March 12, 2025

These suggest that not an insignificant proportion of invasive cancers may also be overdiagnosed as indolent cancers with a very long lead time or cancers that spontaneously regress.”BUFFALO, NY -... read more

Oncotarget

HER2-Low Breast Cancer: Genomic Insights and Evolving Treatment Paradigms

January 22, 2025

Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a new clinical subtype of breast cancer, benefiting from treatment with novel anti-HER2 antibody-drug conjugates.”BUFFALO,... read more

Oncotarget

Tumor Dormancy Initiated by Lymphovascular Embolus

October 30, 2024

Both our experimental as well as observational studies indicate that in vivo lymphovascular tumor emboli and their in vitro spheroid equivalent initiate dormancy through these pathways.”BUFFALO, NY- October 30,... read more

Oncotarget

miR-10b Inhibition: A Strategy for Treating Metastatic Breast Cancer

August 28, 2024

We have developed a nanodrug, termed MN-anti-miR10b, that delivers anti-miR-10b antisense oligomers to cancer cells.”BUFFALO, NY- August 28, 2024 – A new research paper was published in Oncotarget's Volume 15... read more

Oncotarget

Genotype Matters: Tailored Screening for Germline CHEK2 Variants

August 26, 2024

In our study, we postulated that these differences were driven by three common low-risk (LR) missense variants: p.I157T, p.S428F, and p.T476M, all of which have a BC... read more

Oncotarget

Nanobody Inhibits Metastasis of Breast Tumor Cells to Lung in Mice

August 15, 2024

In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.”BUFFALO, NY- August 15, 2024 – A... read more

Oncotarget

HER2-low and HER2-zero in Breast Cancer Between Prognosis, Prediction and Entity

July 16, 2024

we found an independent positive prognostic effect of HER2-low compared to HER2-zero in early breast cancer.”BUFFALO, NY- July 16, 2024 – A new editorial paper was published in Oncotarget's Volume... read more

Figure 2: Analysis of immune cell subsets during neoadjuvant therapy.

Oncotarget

Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer

March 27, 2024

this trial was stopped early after 3 of the first 8 enrolled patients experienced immunotherapy-related toxicity or suspected disease progression [...]”BUFFALO, NY- March 27, 2024 – A new research paper was... read more

Figure 2: Immunoblot assessment of effects on cell-cycle, pro- and anti-apoptosis signaling events mediated by Sacituzumab govitecan plus platinum-based chemotherapeutics in human TNBC, SCLC, and UBC tumor-lines.

Oncotarget

Sacituzumab Govitecan Plus Platinum-based Chemotherapy in Breast, Bladder, and Lung Carcinomas

March 4, 2024

these results support the rationale and potential for favorable clinical outcomes of combining SG therapy with platinum-based chemotherapeutics in solid tumors.”BUFFALO, NY- March 4, 2024 – A new research paper... read more